Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
enliGHten: Long-Term Safety and Efficacy of TransCon hGH in Children With GHD
NCT03344458Phase 3Completed
- Sponsor
- Ascendis Pharma
- Start
- Dec 2017
- Primary completion
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, Prodrugs/Conditional Activator Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of lonapegsomatropin in growth hormone deficiency (GHD), sponsored by Ascendis Pharma. Started Dec 2017; status: completed.
02
Drugs
lonapegsomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT03344458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03344458.